皮膚科治療薬市場レポート 2022-2032
Dermatological Drugs Market Report 2022-2032
レポート詳細
皮膚科治療薬市場レポート 2022-2032 :本レポートは、新たな収益の柱を目指すリーディングカンパニーが、業界とその背景にあるダイナミクスをより深く理解する上で、非常に有益なものと... もっと見る
※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。
サマリー
レポート詳細
皮膚科治療薬市場レポート 2022-2032:本レポートは、新たな収益の柱を目指すリーディングカンパニーが、業界とその背景にあるダイナミクスをより深く理解する上で、非常に有益なものとなるでしょう。また、異業種への進出や新地域での既存事業の拡大を目指す企業にとっても有用なレポートです。
皮膚疾患によるQOLへの影響とそれに対する取り組みが市場成長の原動力
WHO（世界保健機関）は、皮膚疾患の障害を、幸福感、精神衛生、機能能力、社会参加に影響を与え、他者との関わりを制限するものと定義しています。これにはQoL（Quality of Life）ツールが役立ち、ツールにはDLQI（Dermatology Life Quality Index）、Skindexなどがあります。QoLは、主に病気の症状によって様々な理由で損なわれることがあります。アトピー性湿疹は、特に心理的負担が顕著に現れる疾患の一つです。心身症の関与はアトピー性湿疹の大きな特徴であり、治療管理上も考慮されています。さらに、アトピー性皮膚炎におけるQOLは、「湿疹の学校」という名称で、教育プログラムにも取り入れられています。英国では、スコットランドに住む家族を支援するEczema Outreach Scotlandという慈善団体があり、それが次第にイングランド、ウェールズ、北アイルランドの家族支援に拡大し、湿疹の子供を持つことの実際的、感情的側面に焦点を当てたEczema Outreach Supportと名づけられました。
COVID-19後の皮膚科製品の需要増について
消費者や患者の意識が高まり、皮膚科の薬に対する需要が急激に増加しています。また、COVID-19以降、消費者が仕事をするようになり、熱、汚染、ストレスにさらされることで、抗アクネ、美白、抗真菌、エモリエント剤の需要が高まっています。COVID-19で2年間中断された後、皮膚科コンサルティングの訪問者数が増加し、皮膚科医薬品市場の全体的な成長を後押ししています。
マーケットリサーチレポートを購入する前に、どのような質問をすべきでしょうか？
- 皮膚科治療薬市場はどのように進化しているのか？
- 皮膚科治療薬市場の推進要因と抑制要因は何か？
- 予測期間中、各皮膚科治療薬サブマーケットセグメントはどのように成長し、2032年にこれらのサブマーケットが占める収益はどの程度になるのか？
- 2022年から2032年にかけて、各皮膚科治療薬サブマーケットの市場シェアはどのように推移するのか？
- 2022年から2032年にかけて、市場全体の主なドライバーは何になるのか？
- 皮膚科治療薬の主要市場はマクロ経済ダイナミクスに概ね追随するのか、それとも個々の国内市場が他を凌駕するのか？
- 2032年までに各国市場のシェアはどのように変化し、どの地域が2032年に市場をリードするのか？
- 主要プレイヤーは誰か、また予測期間中の見込みは？
- これらの主要企業の皮膚科治療薬プロジェクトはどのようなものなのか？
- 2022年から2032年にかけて、業界はどのように発展していくのか？現在および今後10年間に実施される皮膚科治療薬のプロジェクトはどのような意味を持つのか？
- 皮膚科治療薬市場をさらに拡大するために、製品の商業化の必要性は高いか？
- 皮膚科治療薬市場はどこへ向かっているのか、そして市場の最前線に立つにはどうすればよいのか？
- 新製品やサービスラインに対する最適な投資オプションは何か？
- 企業を新たな成長軌道に乗せ、C-suiteに移行させるための重要な展望とは？
このことが、現在、そして今後10年間の皮膚科治療薬市場にどのような影響を与えるかを知る必要があります。
- 本レポートは、195の表と270のグラフを含む442ページで構成されています。
- このレポートでは、業界における主要な収益性の高い分野に焦点を当て、お客様が今すぐターゲットとできるような情報を提供しています。
- 世界、地域、国別の売上高と成長率を詳細に分析しています。
- 競合他社が成功した主なトレンド、変化、収益予測をハイライトしています。
本レポートは、皮膚科治療薬市場が今後10年間にどのように発展していくのか、またCOVID-19の景気後退や景気回復の変動に伴ってどのように変化していくのかをお伝えします。この市場は、過去10年間のどの時点よりも今が重要です。
2032年までの予測やその他の分析により、商業的な展望が見えてくる
・ In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
・ You will find original analyses, with business outlooks and developments.
・ Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Dermatology Drugs prices and recent developments.
本レポートでは、COVID-19が業界と貴社にどのような影響を与えるかについて、データ分析と貴重な洞察を掲載しています。本レポートでは、COVID-19の4つの回収パターンとその影響、すなわち「V」、「L」、「W」、「U」について論じています。
報告書の対象セグメント
疾患
- 乾癬
- 皮膚炎
- にきび
- 皮膚感染症
- アンチエイジング
- 抗真菌剤
- 皮膚がん
- 抜け毛
- 色素沈着
- その他の疾患
タイプ
- 後発医薬品
- 生物製剤
投与経路
- 局所
- 経口
- 非経口
世界市場全体とセグメントの収益予測に加え、5つの地域とxxの主要な国内市場の収益予測も掲載しています。
北米
- 米国
- カナダ
欧州
- ドイツ
- 英国
- フランス
- スペイン
- イタリア
- ロシア
- その他の欧州
アジア太平洋
- 中国
- 日本
- インド
- オーストラリア
- 韓国
- その他のアジア太平洋地域
ラテンアメリカ
- ブラジル
- メキシコ
- その他のラテンアメリカ地域
MEA
- GCC
- 南アフリカ
- その他のMEA地域
皮膚科治療薬市場の主要企業のプロファイルと2022年から2032年まで、これらの企業の事業のこのセグメントに焦点を当て、含まれています。
主要企業と市場成長の可能性
・ Abbott Laboratories
・ AbbVie
・ Bayer Pharmaceuticals
・ BMS
・ Cipla Pharmaceutical
・ Dr. Reddy’s Laboratories
・ Eli Lilly and Company
・ Glenmark Pharmaceuticals Limited
・ GSK
・ Janssen Pharma
・ Lupin Limited
・ Merck
・ Pfizer
・ Roche
・ Sanofi Pasteur Pharmaceutical
・ Sun Pharmaceutical Industries Limited
・ Taro Pharmaceutical Industries Ltd.
・ Zydus Cadila Healthcare Pharmaceutical
皮膚科治療薬市場の世界全体の収益、2022年から2032年まで金額ベースで市場は2022年に261億米ドルを超えると、我々の仕事は計算しています。また、2032年までの売上高成長率を予測しています。本調査では、最も大きな可能性を秘めた企業を特定します。彼らの能力、進歩、商業的展望を発見することで、一歩先を行くことができます。
皮膚科治療薬市場、2022年から2032年までのレポートはどのように役立つのでしょうか？
440ページを超えるレポートでは、要約すると以下のような知識を得ることができます。
- 皮膚科治療薬市場の2032年までの収益予測、疾患、投与経路、タイプ別の予測、世界および地域レベルでの各予測 - 業界の展望を発見し、投資と収益の最も有利な場所を見つけることができます。
- 5つの地域と21の主要国市場の2032年までの収益予測 - 北米、欧州、アジア太平洋、中南米、MEAの皮膚科薬市場、2022年から2032年の市場予測をご覧ください。また、米国、カナダ、メキシコ、ブラジル、ドイツ、フランス、英国、イタリア、ロシア、中国、インド、日本、オーストラリアなど、主要経済圏の市場も予測しています。
- 既存企業や市場参入を目指す企業の展望 - 皮膚科治療薬市場に関わる主要企業18社の企業プロファイルを含む、2022年から2032年までの展望です。
定量的・定性的な分析と独自の予測をご覧いただけます。私たちのレポートだけが持つ情報を入手し、貴重なビジネスインテリジェンスを得ることができます。
他にはない情報
私たちの新しいレポートがあれば、知識の遅れを取り戻し、チャンスを逃す可能性が低くなります。私たちの研究が貴社の調査、分析、意思決定にどのように役立つかをご覧ください。Visiongainの研究は、皮膚科治療薬市場、2022年から2032年、市場をリードする企業のための商業分析を必要とするすべての人のためのものです。データ、トレンド、予測をご覧いただけます。
ページTOPに戻る
目次
目次
1.レポートの概要
1.1 調査の目的
1.2 皮膚科治療薬市場の紹介
1.3 本レポートが提供するもの
1.4 本レポートを読むべき理由
1.5 本分析報告書が回答する主な質問には以下が含まれる。
1.6 本レポートは誰のためのものなのか？
1.7 方法論
1.7.1 市場の定義
1.7.2 市場評価・予測手法
1.7.3 データの検証
1.8 よくある質問と回答（FAQ）
1.9 関連するVisiongainレポート
1.10 Visiongainについて
2 エグゼクティブサマリー
2.1 地域別スナップショット皮膚科治療薬の世界市場
2.2 疾患別セグメント市場魅力度指数
2.3 投与経路セグメント:3 投与経路セグメント：市場魅力度指標
3 市場の概要
3.1 主要な調査結果
3.2 マーケットダイナミクス
3.2.1 市場の推進要因
3.2.2 市場の抑制要因
3.2.3 市場機会
3.2.4 課題
3.3 COVID-19影響度分析
3.4 ポーターのファイブフォース分析
3.4.1 サプライヤーパワー
3.4.2 バイヤーパワー
3.4.3 競合他社の競争力
3.4.4 代替品による脅威
3.4.5 新規参入者の脅威
4 世界の皮膚科治療薬市場分析：疾患別
4.1 主要な調査結果
4.2 疾患別成長展望
4.3 皮膚科治療薬の世界疾患別市場規模の推定と予測
4.4 乾癬
4.4.1 サブタイプ
4.4.2 利用可能な治療法
4.4.3 乾癬治療の利点とリスク
4.4.4 使用されている主な遺伝子組換え蛋白質治療法
4.4.5 治療にかかる費用
4.4.6 乾癬治療薬のパイプライン
4.4.7 乾癬の地域別市場予測、2022年～2032年、（US$ bn）
4.4.8 乾癬の地域別市場シェア、2022-2032年 (%)
4.5 皮膚炎
4.5.1 刺激性接触皮膚炎
4.5.2 再暴露後のアレルギー反応
4.5.3 皮膚炎パイプライン
4.5.4 皮膚炎の地域別市場予測、2022-2032年（Bn$)
4.5.5 皮膚炎地域別市場シェア、2022-2032年 (%)
4.6 ニキビ
4.6.1 コメド性
4.6.2 丘疹・膿疱性
4.6.3 結節性嚢胞性
4.6.4 利用可能な治療法
4.6.5 レチノイド
4.6.6 抗生物質
4.6.7 抗炎症剤
4.6.8 ホルモン療法
4.6.9 治療の失敗
4.6.10 にきび治療パイプライン
4.6.11 にきび市場の地域別予測、2022年〜2032年（US$ bn）
4.6.12 にきび市場地域別シェア、2022-2032年 (%)
4.7 皮膚感染症
4.7.1 細菌感染症
4.7.2 真菌感染症
4.7.3 ウイルス性感染症
4.7.4 皮膚感染症治療薬パイプライン
4.7.5 皮膚感染症の地域別市場予測、2022年〜2032年（US$ bn）
4.7.6 皮膚感染症地域別市場シェア、2022-2032年 (%)
4.8 アンチエイジング
4.8.1 アンチエイジングの地域別市場予測、2022-2032年（US$ bn）
4.8.2 アンチエイジングの地域別市場シェア、2022-2032年 (%)
4.9 抗真菌剤
4.9.1 抗真菌剤の地域別市場予測、2022-2032年 (Bn米ドル)
4.9.2 抗真菌剤の地域別市場シェア、2022年〜2032年(%)
4.10 皮膚がん
4.10.1 皮膚癌の地域別市場予測, 2022-2032年 (Bn米ドル)
4.10.2 皮膚癌の地域別市場シェア、2022-2032年(%)
4.11 抜け毛
4.11.1 抜け毛の地域別市場予測, 2022-2032年 (Bn米ドル)
4.11.2 抜け毛の地域別市場シェア, 2022-2032年 (%)
4.12 色素沈着症
4.12.1 色素沈着症の地域別市場予測, 2022-2032年 (Bn米ドル)
4.12.2 色素沈着症の地域別市場シェア、2022-2032年(%)
4.13 その他の疾患
4.13.1 その他の疾患の地域別市場予測, 2022-2032年 (Bn米ドル)
4.13.2 その他の疾患の地域別市場シェア、2022-2032年 (%)
5 世界皮膚科治療薬市場分析：投与経路別
5.1 主な調査結果
5.2 投与経路別セグメントの成長展望
5.3 皮膚科治療薬の世界における投与経路別市場規模の推定と予測
5.4 皮膚科治療薬の世界市場 投与経路別シェア、2022年＆2032年
5.5 外用薬
5.5.1 外用剤の地域別市場予測、2022年〜2032年（US$ bn）
5.5.2 外用薬地域別市場シェア、2022年～2032年 (%)
5.6 経口剤
5.6.1 経口剤の地域別市場予測、2022-2032年 (Bn米ドル)
5.6.2 地域別経口市場シェア、2022-2032年(%)
5.7 非経口剤
5.7.1 非経口薬の地域別市場予測, 2022-2032年 (Bn米ドル)
5.7.2 非経口薬の地域別市場シェア、2022-2032年(%)
6 世界の皮膚科治療薬市場分析：後発医薬品／生物学的製剤別
6.1 主な調査結果
6.2 タイプ別セグメント成長見通し
6.3 皮膚科治療薬の後発医薬品／生物学的製剤別世界市場シェア、2022年＆2032年
6.3.1 皮膚科治療薬市場 後発医薬品別
6.3.1.1 後発医薬品市場規模の推定と予測
6.3.2 皮膚科治療薬市場：ブランド薬/生物学的製剤別
6.3.2.1 生物学的製剤の市場規模の推定と予測
7 世界の皮膚科治療薬市場分析：地域別
7.1 主要な調査結果
7.2 地域別市場規模の推定と予測
7.3 COVID-19の影響度分析。回復シナリオ(V, U, W, L)
8 北米の皮膚科治療薬市場分析
8.1 主な調査結果
8.2 北米皮膚科治療薬市場魅力度指数
8.3 北米皮膚科治療薬国別市場 2022年、2027年＆2032年（US$ bn）
8.4 北米皮膚科治療薬市場 国別市場規模予測・予測
8.5 北米皮膚科治療薬市場の疾患別市場規模予測・予測
8.6 北米皮膚科治療薬市場 投与経路別市場規模予測・予測
8.7 米国
8.7.1 米国の皮膚科治療薬市場：疾患別
8.7.2 米国の皮膚科治療薬市場：投与経路
8.8 カナダ
8.8.1 カナダの皮膚科治療薬市場：疾患別
8.8.2 カナダの皮膚科治療薬市場：投与経路別
9 欧州の皮膚科治療薬の市場分析
9.1 主な調査結果
9.2 欧州皮膚科治療薬市場魅力度指数
9.3 欧州皮膚科治療薬国別市場 2022年、2027年＆2032年（US$ bn）
9.4 欧州皮膚科治療薬国別市場規模予測・予測
9.5 欧州皮膚科治療薬の疾患別市場規模予測・予測
9.6 欧州皮膚科治療薬市場 投与経路別市場規模予測・予測
9.7 ドイツ
9.7.1 ドイツの皮膚科治療薬市場：疾患別
9.7.2 ドイツの皮膚科治療薬市場：投与経路
9.8 イギリス
9.8.1 イギリスの皮膚科治療薬市場：疾患別
9.8.2 イギリスの皮膚科用医薬品市場：投与経路別
9.9 フランス
9.9.1 フランスの皮膚科治療薬市場：疾患別
9.9.2 フランスの皮膚科治療薬市場：投与経路別
9.10 イタリア
9.10.1 イタリアの皮膚科治療薬市場：疾患別
9.10.2 イタリアの皮膚科治療薬市場：投与経路別
9.11 スペイン
9.11.1 スペインの皮膚科治療薬市場：疾患別
9.11.2 スペインの皮膚科治療薬市場：投与経路
9.12 ロシア
9.12.1 ロシアの皮膚科治療薬市場：疾患別
9.12.2 ロシアの皮膚科治療薬市場：投与経路
9.13 欧州以外の地域
9.13.1 欧州の皮膚科治療薬市場：疾患別
9.13.2 欧州の皮膚科治療薬市場：投与経路別
10 アジア太平洋地域の皮膚科治療薬市場分析
10.1 主な調査結果
10.2 アジア太平洋地域の皮膚科治療薬市場魅力度指数
10.3 アジア太平洋地域の皮膚科治療薬国別市場 2022年、2027年＆2032年（US$ bn）
10.4 アジア太平洋地域の皮膚科用医薬品の国別市場規模予測・予想
10.5 アジア太平洋地域の皮膚科治療薬市場の疾患別市場規模予測と予測
10.6 アジア太平洋地域の皮膚科治療薬市場の投与経路別市場規模予測・予測
10.7 日本
10.7.1 日本の皮膚科治療薬市場：疾患別
10.7.2 日本皮膚科治療薬市場：投与経路別
10.8 中国
10.8.1 中国の皮膚科治療薬市場：疾患別
10.8.2 中国の皮膚科治療薬市場：投与経路別
10.9 インド
10.9.1 インドの皮膚科治療薬市場：疾患別
10.9.2 インドの皮膚科治療薬市場：投与経路別
10.10 韓国
10.10.1 韓国の皮膚科治療薬市場：疾患別
10.10.2 韓国の皮膚科治療薬市場：投与経路別
10.11 オーストラリア
10.11.1 オーストラリアの皮膚科治療薬市場：疾患別
10.11.2 オーストラリアの皮膚科治療薬市場：投与経路別
10.12 APACのその他の地域
10.12.1 APACその他の地域：皮膚科治療薬市場：疾患別
10.12.2 APAC諸国の皮膚科用医薬品市場：投与経路別
11 ラテンアメリカの皮膚科治療薬市場分析
11.1 主な調査結果
11.2 ラテンアメリカの皮膚科治療薬市場魅力度指数
11.3 ラテンアメリカの皮膚科治療薬国別市場 2022年、2027年＆2032年（US$ bn）
11.4 ラテンアメリカの皮膚科治療薬市場 国別市場規模予測・予想
11.5 ラテンアメリカの皮膚科治療薬市場規模予測・疾患別予測
11.6 ラテンアメリカの皮膚科治療薬市場の投与経路別市場規模予測・予測
11.7 ブラジル
11.7.1 ブラジル皮膚科治療薬市場：疾患別
11.7.2 ブラジルの皮膚科治療薬市場：投与経路別
11.8 メキシコ
11.8.1 メキシコの皮膚科治療薬市場：疾患別
11.8.2 メキシコの皮膚科治療薬市場：投与経路別
11.9 ラテンアメリカのその他の地域
11.9.1 ラテンアメリカのその他の地域：皮膚科用医薬品市場：疾患別
11.9.2 ラテンアメリカのその他の地域：皮膚科用医薬品市場：投与経路別
12 MEAの皮膚科治療薬市場分析
12.1 主な調査結果
12.2 MEA皮膚科治療薬市場魅力度指数
12.3 MEA皮膚科治療薬国別市場 2022年、2027年＆2032年（US$ bn）
12.4 MEA皮膚科治療薬市場の国別市場規模予測・予想
12.5 MEA皮膚科治療薬市場の疾患別市場規模予測・予測
12.6 MEA皮膚科治療薬市場の投与経路別市場規模予測・予測
12.7 南アフリカ
12.7.1 南アフリカの皮膚科治療薬市場：疾患別
12.7.2 南アフリカの皮膚科治療薬市場：投与経路別
12.8 GCC
12.8.1 GCCの皮膚科治療薬市場：疾患別
12.8.2 GCCの皮膚科治療薬市場：投与経路別
12.9 MEAのその他の地域
12.9.1 MEAその他の地域：皮膚科治療薬市場：疾患別
12.9.2 MEAの皮膚科用医薬品市場：投与経路別
13 競合他社の状況
13.1 企業シェア分析
13.2 主要事業戦略分析
14 主要企業のプロフィール
14.1 ファイザー
14.1.1 企業スナップショット
14.1.2 会社概要
14.1.3 財務分析
14.1.4 製品ベンチマーク
14.1.5 戦略的展望
14.2 メルク
14.2.1 会社概要
14.2.2 会社概要
14.2.3 財務分析
14.2.4 製品ベンチマーク
14.2.5 戦略的展望
14.3 GSK
14.3.1 企業スナップショット
14.3.2 会社概要
14.3.3 財務分析
14.3.4 製品ベンチマーク
14.3.5 戦略的展望
14.4 アッヴィ
14.4.1 企業スナップショット
14.4.2 会社概要
14.4.3 財務分析
14.4.4 製品ベンチマーク
14.4.5 戦略的展望
14.5 ヤンセンファーマ
14.5.1 企業スナップショット
14.5.2 会社概要
14.5.3 財務分析
14.5.4 製品ベンチマーク
14.5.5 戦略的展望
14.6 BMS
14.6.1 企業スナップショット
14.6.2 会社概要
14.6.3 財務分析
14.6.4 製品ベンチマーク
14.6.5 戦略的展望
14.7 ロシュ
14.7.1 企業スナップショット
14.7.2 会社概要
14.7.3 財務分析
14.7.4 製品ベンチマーク
14.7.5 戦略的展望
14.8 アボット・ラボラトリーズ
14.8.1 企業スナップショット
14.8.2 会社概要
14.8.3 財務分析
14.8.4 製品ベンチマーク
14.8.5 戦略的展望
14.9 バイエル薬品
14.9.1 企業スナップショット
14.9.2 会社概要
14.9.3 財務分析
14.9.4 製品ベンチマーク
14.9.5 戦略的展望
14.10 ザイダス・カディラ・ヘルスケア・ファーマシューティカル
14.10.1 企業スナップショット
14.10.2 会社概要
14.10.3 財務分析
14.10.4 製品ベンチマーク
14.10.5 戦略的展望
14.11 シプラ・ファーマシューティカル
14.11.1 企業スナップショット
14.11.2 会社概要
14.11.3 財務分析
14.11.4 製品ベンチマーク
14.11.5 戦略的な展望
14.12 ドクター・レディーズ・ラボラトリーズ
14.12.1 企業スナップショット
14.12.2 会社概要
14.12.3 財務分析
14.12.4 製品ベンチマーク
14.12.5 戦略的な展望
14.13 イーライリリー・アンド・カンパニー
14.13.1 企業スナップショット
14.13.2 会社概要
14.13.3 財務分析
14.13.4 製品ベンチマーク
14.13.5 戦略的展望
14.14 グレンマーク・ファーマシューティカルズ・リミテッド
14.14.1 企業スナップショット
14.14.2 会社概要
14.14.3 財務分析
14.14.4 製品ベンチマーク
14.14.5 戦略的な展望
14.15 ルパン・リミテッド
14.15.1 企業スナップショット
14.15.2 会社概要
14.15.3 財務分析
14.15.4 製品ベンチマーク
14.15.5 戦略的展望
14.16 サノフィパスツール製薬
14.16.1 企業スナップショット
14.16.2 会社概要
14.16.3 財務分析
14.16.4 製品ベンチマーク
14.16.5 戦略的展望
14.17 サンファーマシューティカルインダストリー
14.17.1 企業スナップショット
14.17.2 会社概要
14.17.3 財務分析
14.17.4 製品ベンチマーク
14.17.5 戦略的展望
14.18 太郎製薬
14.18.1 企業スナップショット
14.18.2 会社概要
14.18.3 財務分析
14.18.4 製品ベンチマーク
14.18.5 戦略的展望
15 結論と提言
15.1 ビジョンゲインからの結論
15.2 市場関係者への提言
表の一覧
Table 1 Global Dermatology Drugs Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 Dermatology Drugs Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (V-shaped Recovery)
Table 3 Dermatology Drugs Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (U-shaped Recovery)
Table 4 Dermatology Drugs Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (W-shaped Recovery)
Table 5 Dermatology Drugs Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (L-shaped Recovery)
Table 6 Dermatological Drugs Diseases Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 7 Cost of Psoriasis Therapies in A Typical Western European Country ($)
Table 8 Psoriasis Drug Pipeline
Table 9 Psoriasis Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 10 Global Products Undergoing Research as Potential Treatments for Dermatitis
Table 11 Dermatitis Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 12 Global Potential Products for Acne Treatment
Table 13 Acne Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 14 Global Antifungals for Superficial Fungal Infections
Table 15 Global Antiviral Drugs Available
Table 16 Global Potential Drug Candidates for Skin Infection Treatments
Table 17 Skin Infection Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 18 Antiaging Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 19 Antifungal Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 20 Skin cancer Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 21 Hair Loss Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 22 Hyperpigmentation Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 23 Other Diseases Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 24 Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 25 Topical Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 26 Oral Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 27 Parenteral Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 28 Dermatological Drugs Generics Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 29 Dermatological Drugs Biologics Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 30 Dermatological Drugs Market, By Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 31 Dermatology Drugs Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (V-shaped Recovery)
Table 32 Dermatology Drugs Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (U-shaped Recovery)
Table 33 Dermatology Drugs Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (W-shaped Recovery)
Table 34 Dermatology Drugs Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (L-shaped Recovery)
Table 35 North America Dermatological Drugs Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 36 North America Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 37 North America Dermatological Drugs Market by Psoriasis Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 38 North America Dermatological Drugs Market by Dermatitis Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 39 North America Dermatological Drugs Market by Acne Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 40 North America Dermatological Drugs Market by Skin Infections Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 41 North America Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 42 US Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 43 US Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 44 US Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 45 Canada Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 46 Canada Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 47 Canada Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 48 Europe Dermatological Drugs Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 49 Europe Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 50 Europe Dermatological Drugs Market by Psoriasis Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 51 Europe Dermatological Drugs Market by Dermatitis Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 52 Europe Dermatological Drugs Market by Acne Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 53 Europe Dermatological Drugs Market by Skin Infections Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 54 Europe Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 55 Germany Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 56 Germany Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 57 Germany Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 58 UK Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 59 UK Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 60 UK Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 61 France Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 62 France Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 63 France Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 64 Italy Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 65 Italy Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 66 Italy Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 67 Spain Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 68 Spain Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 69 Spain Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 70 Russia Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 71 Russia Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 72 Russia Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 73 Rest of Europe Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 74 Rest of Europe Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 75 Rest of Europe Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 76 Asia Pacific Dermatological Drugs Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 77 Asia Pacific Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 78 Asia-Pacific Dermatological Drugs Market by Psoriasis Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 79 Asia-Pacific Dermatological Drugs Market by Dermatitis Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 80 Asia-Pacific Dermatological Drugs Market by Acne Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 81 Asia-Pacific Dermatological Drugs Market by Skin Infections Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 82 Asia Pacific Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 83 Japan Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 84 Japan Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 85 Japan Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 86 China Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 87 China Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 88 China Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 89 India Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 90 India Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 91 India Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 92 South Korea Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 93 South Korea Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 94 South Korea Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 95 Australia Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 96 Australia Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 97 Australia Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 98 Rest of Asia Pacific Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 99 Rest of Asia Pacific Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 100 Rest of Asia Pacific Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 101 Latin America Dermatological Drugs Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 102 Latin America Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 103 LATAM Dermatological Drugs Market by Psoriasis Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 104 LATAM Dermatological Drugs Market by Dermatitis Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 105 LATAM Dermatological Drugs Market by Acne Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 106 LATAM Dermatological Drugs Market by Skin Infections Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 107 Latin America Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 108 Brazil Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 109 Brazil Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 110 Brazil Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 111 Mexico Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 112 Mexico Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 113 Mexico Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 114 Rest of Latin America Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 115 Rest of LATAM Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 116 Rest of LATAM Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 117 MEA Dermatological Drugs Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 118 MEA Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 119 MEA Dermatological Drugs Market by Psoriasis Drugs, 2022-2032 (USD Bn, AGR (%), CAGR(%))
Table 120 MEA Dermatological Drugs Market by Dermatitis Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 121 MEA Dermatological Drugs Market by Acne Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 122 MEA Dermatological Drugs Market by Skin Infections Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 123 MEA Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 124 South Africa Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 125 South Africa Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 126 South Africa Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 127 GCC Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 128 GCC Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 129 GCC Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 130 Rest of MEA Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 131 Rest of MEA Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 132 Rest of MEA Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 133 Key Business Strategies Adopted by Key Players in Global Dermatology Drugs Market
Table 134 Pfizer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 135 Pfizer: Product Benchmarking
Table 136 Pfizer Inc: Company Product Pipeline
Table 137 Pfizer Inc: Company Recent Developments
Table 138 Merck: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 139 Merck: Product Benchmarking
Table 140 Merck: Company Recent Developments
Table 141 GSK: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 142 GSK: Product Benchmarking
Table 143 GlaxoSmithKline: Company Product Pipeline
Table 144 GlaxoSmithKline: Company Recent Developments
Table 145 AbbVie: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
Table 146 AbbVie: Product Benchmarking
Table 147 AbbVie Inc: Company Product Pipeline
Table 148 AbbVie Inc: Company Recent Developments
Table 149 Janssen Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 150 Janssen Pharma: Product Benchmarking
Table 151 Janssen Pharma: Company Product Pipeline
Table 152 Janssen Pharma: Company Recent Developments
Table 153 BMS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
Table 154 BMS: Product Benchmarking
Table 155 Bristol-Myers Squibb: Company Product Pipeline
Table 156 Bristol-Myers Squibb: Company Recent Developments
Table 157 Roche: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 158 Roche: Product Benchmarking
Table 159 F. Hoffmann-La Roche Ltd: Company Recent Developments
Table 160 Abbott Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 161 Bayer Pharmaceuticals: Product Benchmarking
Table 162 Bayer Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 163 Bayer Pharmaceuticals: Product Benchmarking
Table 164 Bayer Pharmaceuticals: Company Recent Developments
Table 165 Zydus Cadila Healthcare Pharmaceutical: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 166 Zydus Cadila Healthcare Pharmaceutical: Product Benchmarking
Table 167 Zydus Cadila Healthcare Pharmaceuticals: Company Recent Developments
Table 168 Cipla Pharmaceutical: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 169 Cipla Pharmaceutical: Product Benchmarking
Table 170 Cipla Pharmaceutical: Company Recent Developments
Table 171 Dr. Reddy’s Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 172 Dr. Reddy’s Laboratories: Product Benchmarking
Table 173 Dr. Reddy’s Laboratories: Company Recent Developments
Table 174 Eli Lilly and Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 175 Eli Lilly and Company: Product Benchmarking
Table 176 Eli Lilly and Company: Company Product Pipeline
Table 177 Eli Lilly and Company: Company Recent Developments
Table 178 Glenmark Pharmaceuticals Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 179 Glenmark Pharmaceuticals Limited: Product Benchmarking
Table 180 Glenmark Pharmaceuticals Limited: Company Product Pipeline
Table 181 Glenmark Pharmaceuticals Limited: Company Recent Developments
Table 182 Lupin Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 183 Lupin Limited: Product Benchmarking
Table 184 Lupin Limited: Company Recent Developments
Table 185 Sanofi Pasteur Pharmaceutical: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 186 Sanofi Pasteur Pharmaceutical: Product Benchmarking
Table 187 Sanofi Pasteur Pharmaceutical: Company Product Pipeline
Table 188 Sanofi Pasteur Pharmaceutical: Company Recent Developments
Table 189 Sun Pharmaceutical Industries Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 190 Sun Pharmaceutical Industries Limited: Product Benchmarking
Table 191 Sun Pharmaceutical Industries Limited: Company Product Pipeline
Table 192 Sun Pharmaceutical Industries Limited: Company Recent Developments
Table 193 Taro Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 194 Taro Pharmaceutical Industries Ltd.: Product Benchmarking
Table 195 Taro Pharmaceutical Industries Ltd: Company Recent Developments
図の一覧
Figure 1 Global Dermatology Drugs Market Segmentation
Figure 2 Global Dermatology Drugs Market Forecast by Region: Market Attractiveness Index
Figure 3 Global Dermatology Drugs Market by Disease: Market Attractiveness Index
Figure 4 Global Dermatology Drugs Market by Route of Administration: Market Attractiveness Index
Figure 5 Global Dermatology Drugs Market: Market Dynamics
Figure 6 Global COVID Impact Analysis: Dermatology Drugs Market Recovery Scenarios
Figure 7 Global Dermatology Drugs Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 8 Global Dermatology Drugs Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 9 Global Dermatology Drugs Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 10 Global Dermatology Drugs Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 11 Global Dermatology Drugs Market: Porter’s Five Forces Analysis
Figure 12 Global Dermatology Drugs Market Forecast by Disease 2022, 2027, 2032 (Revenue, CAGR %)
Figure 13 Global Dermatology Drugs Market Share Forecast by Disease, 2022, 2027, 2032 (%)
Figure 14 Global Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 15 Psoriasis Market Forecast by Region, 2022-2032 (US$ billion)
Figure 16 Psoriasis Market Share Forecast by Region, 2022-2032 (%)
Figure 17 Dermatitis Market Forecast by Region, 2022-2032 (US$ billion)
Figure 18 Dermatitis Market Share Forecast by Region, 2022-2032 (%)
Figure 19 Acne Market Forecast by Region, 2022-2032 (US$ billion)
Figure 20 Acne Market Share Forecast by Region, 2022-2032 (%)
Figure 21 Skin Infections Market Forecast by Region, 2022-2032 (US$ billion)
Figure 22 Skin Infections Market Share Forecast by Region, 2022-2032 (%)
Figure 23 Antiaging Market Forecast by Region, 2022-2032 (US$ billion)
Figure 24 Antiaging Market Share Forecast by Region, 2022-2032 (%)
Figure 25 Antifungal Market Forecast by Region, 2022-2032 (US$ billion)
Figure 26 Antifungal Market Share Forecast by Region, 2022-2032 (%)
Figure 27 Skin Cancer Market Forecast by Region, 2022-2032 (US$ billion)
Figure 28 Skin Cancer Market Share Forecast by Region, 2022-2032 (%)
Figure 29 Hair Loss Market Forecast by Region, 2022-2032 (US$ billion)
Figure 30 Hair Loss Market Share Forecast by Region, 2022-2032 (%)
Figure 31 Hyperpigmentation Market Forecast by Region, 2022-2032 (US$ billion)
Figure 32 Hyperpigmentation Market Share Forecast by Region, 2022-2032 (%)
Figure 33 Other Disease Market Forecast by Region, 2022-2032 (US$ billion)
Figure 34 Other Disease Market Share Forecast by Region, 2022-2032 (%)
Figure 35 Global Dermatology Drugs Market Forecast by Route of Administration 2022, 2027, 2032 (Revenue, CAGR%)
Figure 36 Global Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 37 Global Dermatology Drugs Market Share Forecast by Route of Administration, 2022, 2032 (%)
Figure 38 Topical Market Forecast by Region, 2022-2032 (US$ billion)
Figure 39 Topical Market Share Forecast by Region, 2022-2032 (%)
Figure 40 Oral Market Forecast by Region, 2022-2032 (US$ billion)
Figure 41 Oral Market Share Forecast by Region, 2022-2032 (%)
Figure 42 Parenteral Market Forecast by Region, 2022-2032 (US$ billion)
Figure 43 Parenteral Market Share Forecast by Region, 2022-2032 (%)
Figure 44 Global Dermatology Drugs Market Forecast by Generics/Biologics 2022, 2027, 2032 (Revenue, CAGR %)
Figure 45 Global Dermatology Drugs Market Share Forecast by Generics/Biologics, 2022, 2032 (%)
Figure 46 Global Dermatology Drugs Market Forecast by Generics, 2022-2032 (US$ billion, AGR %)
Figure 47 Global Dermatology Drugs Market Forecast by Biologics, 2022-2032 (US$ billion, AGR %)
Figure 48 Global Dermatology Drugs Market Forecast by Region 2022, 2027, 2032 (Revenue), C
Figure 49 Global Dermatology Drugs Market Share Forecast by Region 2022, 2027, 2032(%)
Figure 50 Global Dermatology Drugs Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Figure 51 Global Dermatology Drugs Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 52 Global Dermatology Drugs Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 53 Global Dermatology Drugs Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 54 Global Dermatology Drugs Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 55 North America Dermatology Drugs Market Attractiveness Index, 2022
Figure 56 North America Dermatology Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 57 North America Dermatology Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 58 North America Dermatology Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 59 North America Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 60 North America Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 61 North America Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 62 North America Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 63 U.S. Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 64 U.S. Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 65 U.S. Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 66 U.S. Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 67 U.S. Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 68 Canada Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 69 Canada Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 70 Canada Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 71 Canada Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 72 Canada Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 73 Europe Dermatology Drugs Market Attractiveness Index
Figure 74 Europe Dermatology Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 75 Europe Dermatology Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 76 Europe Dermatology Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 77 Europe Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 78 Europe Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 79 Europe Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 80 Europe Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 81 Germany Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 82 Germany Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 83 Germany Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 84 Germany Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 85 Germany Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 86 UK Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 87 U.K. Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 88 U.K. Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 89 U.K. Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 90 U.K. Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 91 France Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 92 France Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 93 France Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 94 France Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 95 France Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 96 Italy Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 97 Italy Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 98 Italy Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 99 Italy Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 100 Italy Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 101 Spain Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 102 Spain Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 103 Spain Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 104 Spain Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 105 Spain Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 106 Russia Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 107 Russia Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 108 Russia Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 109 Russia Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 110 Russia Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 111 Rest of Europe Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 112 Rest of Europe Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 113 Rest of Europe Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 114 Rest of Europe Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 115 Rest of Europe Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 116 Asia Pacific Dermatology Drugs Market Attractiveness Index
Figure 117 Asia Pacific Dermatology Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 118 Asia Pacific Dermatology Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 119 Asia Pacific Dermatology Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 120 Asia Pacific Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 121 Asia Pacific Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 122 Asia Pacific Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 123 Asia Pacific Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 124 Japan Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 125 Japan Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 126 Japan Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 127 Japan Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 128 Japan Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 129 China Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 130 China Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 131 China Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 132 China Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 133 China Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 134 India Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 135 India Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 136 India Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 137 India Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 138 India Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 139 South Korea Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 140 South Korea Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 141 South Korea Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 142 South Korea Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 143 South Korea Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 144 Australia Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 145 Australia Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 146 Australia Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 147 Australia Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 148 Australia Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 149 Rest of Asia Pacific Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 150 Rest of APAC Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 151 Rest of APAC Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 152 Rest of APAC Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 153 Rest of APAC Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 154 Latin America Dermatology Drugs Market Attractiveness Index
Figure 155 Latin America Dermatology Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 156 Latin America Dermatology Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 157 Latin America Dermatology Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 158 Latin America Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 159 Latin America Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 160 Latin America Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 161 Latin America Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 162 Brazil Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 163 Brazil Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 164 Brazil Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 165 Brazil Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 166 Brazil Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 167 Mexico Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 168 Mexico Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 169 Mexico Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 170 Mexico Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 171 Mexico Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 172 Rest of LATAM Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 173 Rest of LATAM Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 174 Rest of LATAM Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 175 Rest of LATAM Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 176 Rest of LATAM Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 177 MEA Dermatology Drugs Market Attractiveness Index
Figure 178 MEA Dermatology Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 179 MEA Dermatology Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 180 MEA Dermatology Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 181 MEA Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 182 MEA Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 183 MEA Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 184 MEA Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 185 South Africa Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 186 South Africa Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 187 South Africa Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 188 South Africa Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 189 South Africa Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 190 GCC Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 191 GCC Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 192 GCC Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 193 GCC Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 194 GCC Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 195 Rest of MEA Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 196 Rest of MEA Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 197 Rest of MEA Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 198 Rest of MEA Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 199 Rest of MEA Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 200 Global Dermatology Drugs Market: Company Ranking Analysis, 2021
Figure 201 Pfizer: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 202 Pfizer: Regional Market Shares, 2021
Figure 203 Pfizer: Gross Profit, 2019-2021 (US$ million, AGR%)
Figure 204 Pfizer: R&D, 2019-2021 (US$ million, AGR%)
Figure 205 Merck: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 206 Merck: Regional Market Shares, 2021
Figure 207 Merck: Income from Continuing Operations before Taxes, 2019-2021 (US$ million, AGR %)
Figure 208 Merck: R&D, 2019-2021 (US$ million, AGR %)
Figure 209 GSK: Net Revenue, 2019-2021 (US$ million, AGR %)
Figure 210 GSK: Regional Market Shares, 2021
Figure 211 GSK: Gross Profit, 2019-2021 (US$ million, AGR %)
Figure 212 GSK: R&D, 2019-2021 (US$ million, AGR %)
Figure 213 AbbVie: Net Revenue, 2019-2021 (US$ million, AGR %)
Figure 214 AbbVie: Regional Market Shares, 2021
Figure 215 AbbVie: Operating Earnings, 2019-2021 (US$ million, AGR %)
Figure 216 AbbVie: R&D, 2019-2021 (US$ million, AGR %)
Figure 217 Janssen Pharma: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 218 Janssen Pharma: Regional Market Shares, 2021
Figure 219 Janssen Pharma: Gross Profit, 2019-2021 (US$ million, AGR%)
Figure 220 Janssen Pharma: R&D, 2019-2021 (US$ million, AGR%)
Figure 221 BMS: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 222 BMS: Regional Market Shares, 2021
Figure 223 BMS: Net Earnings, 2019-2021 (US$ million, AGR%)
Figure 224 BMS: R&D, 2019-2021 (US$ million, AGR %)
Figure 225 Roche: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 226 Roche: Regional Market Shares, 2021
Figure 227 Roche: Operating Profit, 2019-2021 (US$ million, AGR%)
Figure 228 Roche: R&D, 2019-2021 (US$ million, AGR%)
Figure 229 Abbott Laboratories: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 230 Abbott Laboratories: Regional Market Shares, 2021
Figure 231 Abbott Laboratories: Net Earnings, 2019-2021 (US$ million, AGR%)
Figure 232 Abbott Laboratories: R&D, 2019-2021 (US$ million, AGR%)
Figure 233 Bayer Pharmaceuticals: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 234 Bayer Pharmaceuticals: Regional Market Shares, 2021
Figure 235 Bayer Pharmaceuticals: EBITDA, 2019-2021 (US$ million, AGR%)
Figure 236 Bayer Pharmaceuticals: R&D, 2019-2021 (US$ million, AGR%)
Figure 237 Zydus Cadila Healthcare Pharmaceutical: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 238 Zydus Cadila Healthcare Pharmaceutical: Regional Market Shares, 2021
Figure 239 Zydus Cadila Healthcare Pharmaceutical: Net Profit, 2019-2021 (US$ million, AGR%)
Figure 240 Zydus Cadila Healthcare Pharmaceutical: R&D, 2019-2021 (US$ million, AGR%)
Figure 241 Cipla Pharmaceutical: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 242 Cipla Pharmaceutical: Regional Market Shares, 2021
Figure 243 Cipla Pharmaceutical: EBITDA, 2019-2021 (US$ million, AGR%)
Figure 244 Cipla Pharmaceutical: R&D, 2019-2021 (US$ million, AGR%)
Figure 245 Dr. Reddy’s Laboratories: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 246 Dr. Reddy’s Laboratories: Regional Market Shares, 2021
Figure 247 Dr. Reddy’s Laboratories: EBITDA, 2019-2021 (US$ million, AGR%)
Figure 248 Dr. Reddy’s Laboratories: R&D, 2019-2021 (US$ million, AGR%)
Figure 249 Eli Lilly and Company: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 250 Eli Lilly and Company: Regional Market Shares, 2021
Figure 251 Eli Lilly and Company: Net Income, 2019-2021 (US$ million, AGR%)
Figure 252 Eli Lilly and Company: R&D, 2019-2021 (US$ million, AGR%)
Figure 253 Glenmark Pharmaceuticals Limited: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 254 Glenmark Pharmaceuticals Limited: Regional Market Shares, 2021
Figure 255 Lupin Limited: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 256 Lupin Limited: Regional Market Shares, 2021
Figure 257 Lupin Limited: Net Profit/Loss, 2019-2021 (US$ million, AGR%)
Figure 258 Lupin Limited: R&D, 2019-2021 (US$ million, AGR%)
Figure 259 Sanofi Pasteur Pharmaceutical: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 260 Sanofi Pasteur Pharmaceutical: Regional Market Shares, 2021
Figure 261 Sanofi Pasteur Pharmaceutical: Net Income, 2019-2021 (US$ million, AGR%)
Figure 262 Sanofi Pasteur Pharmaceutical: R&D, 2019-2021 (US$ million, AGR%)
Figure 263 Sun Pharmaceutical Industries Limited: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 264 Sun Pharmaceutical Industries Limited: Regional Market Shares, 2021
Figure 265 Sun Pharmaceutical Industries Limited: Net Profit/Loss, 2019-2021 (US$ million, AGR%)
Figure 266 Sun Pharmaceutical Industries Limited: R&D, 2019-2021 (US$ million, AGR%)
Figure 267 Taro Pharmaceutical Industries Ltd.: Net Revenue, 2020-2022 (US$ million, AGR%)
Figure 268 Taro Pharmaceutical Industries Ltd.: Regional Market Shares, 2022
Figure 269 Taro Pharmaceutical Industries Ltd.: Net Income, 2020-2022 (US$ million, AGR%)
Figure 270 Taro Pharmaceutical Industries Ltd.: R&D, 2020-2022 (US$ million, AGR%)
ページTOPに戻る
Summary
Report Details
The Dermatology Drugs Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Factors Such As the Impact of Skin Disease on Quality Of Life and the Resulting Need to Tackle This Are Driving the Market Growth
WHO (World Health Organization) defined it as disability in skin conditions that impact the well-being, mental health, ability to function, and social participation and restrict engagement with others. Quality of life (QoL) tools help in these and some of the tools include the Dermatology Life Quality Index (DLQI) and the Skindex. The QoL can be impaired for a variety of reasons mainly due to symptoms of the disease. Atopic eczema is one disease where the psychological burden is particularly pronounced. Psychosomatic involvement is the main characteristic of atopic eczema and is considered in therapeutic management. Furthermore, QOL in atopic dermatitis has also been included in educational programs, under the name ‘eczema school’. In the UK, there is a charity called Eczema Outreach Scotland that supported families living in Scotland that gradually expanded to support families in England, Wales, and Northern Ireland and was named Eczema Outreach Support with a focus on practical and emotional aspects of having a child with eczema.
The rise in demand for dermatological products post COVID-19
There has been a sudden surge in demand for dermatological drugs as consumers and patients are becoming more aware and conscious. Moreover, as consumers presume their work post-COVID-19, exposure to heat, pollution, and stress has boosted the demand for anti-acne, skin brightening, anti-fungal, and emollients. With a long hiatus of 2 years due to COVID-19, there has been a rise in footfall observed for dermatology consulting thereby boosting the overall growth of the dermatology drugs market.
What Questions Should You Ask before Buying a Market Research Report?
• How is the Dermatology Drugs Market evolving?
• What is driving and restraining the Dermatology Drugs Market?
• How will each dermatology drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each Dermatology Drugs submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading Dermatology Drugs Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Dermatology Drugs projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implications of Dermatology Drugs projects taking place now and over the next 10 years?
• Is there a greater need for product commercialization to further scale the Dermatology Drugs Market?
• Where is the Dermatology Drugs Market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Dermatology Drugs Market today, and over the next 10 years:
• Our 442-page report provides 195 tables and 270 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Dermatology Drugs Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Dermatology Drugs prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Disease
• Psoriasis
• Dermatitis
• Acne
• Skin Infection
• Antiaging
• Antifungal
• Skin Cancer
• Hair Loss
• Hyperpigmentation
• Other Diseases
Type
• Generics
• Biologics
Route of Administration
• Topical
• Oral
• Parenteral
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and xx leading national markets:
North America
• U.S.
• Canada
Europe
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
MEA
• GCC
• South Africa
• Rest of MEA
The report also includes profiles and for some of the leading companies in the Dermatology Drugs Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• Abbott Laboratories
• AbbVie
• Bayer Pharmaceuticals
• BMS
• Cipla Pharmaceutical
• Dr. Reddy’s Laboratories
• Eli Lilly and Company
• Glenmark Pharmaceuticals Limited
• GSK
• Janssen Pharma
• Lupin Limited
• Merck
• Pfizer
• Roche
• Sanofi Pasteur Pharmaceutical
• Sun Pharmaceutical Industries Limited
• Taro Pharmaceutical Industries Ltd.
• Zydus Cadila Healthcare Pharmaceutical
Overall world revenue for the Dermatology Drugs Market, 2022 to 2032 in terms of value the market will surpass US$26.1 billion in 2022, our work calculates. We predict strong revenue growth through 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Dermatology Drugs Market, 2022 to 2032 report help you?
In summary, our 440+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for Dermatology Drugs Market, 2022 to 2032 Market, with forecasts for disease, route of administration, type, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2032 for five regional and 21 key national markets – See forecasts for the Dermatology Drugs Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Russia, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 18 of the major companies involved in the Dermatology Drugs Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Dermatology Drugs Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.
ページTOPに戻る
Table of Contents
Table of Contents
1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Dermatology Drugs Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered By This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
2.1 Geographical Snapshot: Global Dermatology Drugs Market
2.2 Disease Segment: Market Attractiveness Index
2.3 Route of Administration Segment: Market Attractiveness Index
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.2 Market Restraining Factors
3.2.3 Market Opportunities
3.2.4 Challenges
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
4 Global Dermatology Drugs Market Analysis by Disease
4.1 Key Findings
4.2 Disease Segment Growth Prospects
4.3 Global Dermatology Drugs Market Size Estimation and Forecast by Disease
4.4 Psoriasis
4.4.1 Subtypes
4.4.2 Treatments Available
4.4.3 Psoriasis Treatment Benefits and Risks
4.4.4 Major Engineered Protein Treatments In Use
4.4.5 Cost of Treatment
4.4.6 Psoriasis Treatment Pipeline
4.4.7 Psoriasis Market Forecast by Region, 2022-2032 (US$ Bn)
4.4.8 Psoriasis Market Share by Region, 2022-2032 (%)
4.5 Dermatitis
4.5.1 Irritant Contact Dermatitis
4.5.2 Allergic response after re-exposure.
4.5.3 Dermatitis Pipeline
4.5.4 Dermatitis Market Forecast by Region, 2022-2032 (US$ Bn)
4.5.5 Dermatitis Market Share by Region, 2022-2032 (%)
4.6 Acne
4.6.1 Comedonal
4.6.2 Papulopustular
4.6.3 Nodulocystic
4.6.4 Treatments Available
4.6.5 Retinoids
4.6.6 Antibiotics
4.6.7 Anti-inflammatory Drugs
4.6.8 Hormonal Therapy
4.6.9 Treatment Failure
4.6.10 Acne Treatment Pipeline
4.6.11 Acne Market Forecast by Region, 2022-2032 (US$ Bn)
4.6.12 Acne Market Share by Region, 2022-2032 (%)
4.7 Skin Infections
4.7.1 Bacterial Infections
4.7.2 Fungal Infections
4.7.3 Viral Infections
4.7.4 Skin Infection Treatment Pipeline
4.7.5 Skin Infections Market Forecast by Region, 2022-2032 (US$ Bn)
4.7.6 Skin Infections Market Share by Region, 2022-2032 (%)
4.8 Antiaging
4.8.1 Antiaging Market Forecast by Region, 2022-2032 (US$ Bn)
4.8.2 Antiaging Market Share by Region, 2022-2032 (%)
4.9 Antifungal
4.9.1 Antifungal Market Forecast by Region, 2022-2032 (US$ Bn)
4.9.2 Antifungal Market Share by Region, 2022-2032 (%)
4.10 Skin Cancer
4.10.1 Skin Cancer Market Forecast by Region, 2022-2032 (US$ Bn)
4.10.2 Skin Cancer Market Share by Region, 2022-2032 (%)
4.11 Hair Loss
4.11.1 Hair Loss Market Forecast by Region, 2022-2032 (US$ Bn)
4.11.2 Hair Loss Market Share by Region, 2022-2032 (%)
4.12 Hyperpigmentation
4.12.1 Hyperpigmentation Market Forecast by Region, 2022-2032 (US$ Bn)
4.12.2 Hyperpigmentation Market Share by Region, 2022-2032 (%)
4.13 Other diseases
4.13.1 Other Diseases Market Forecast by Region, 2022-2032 (US$ Bn)
4.13.2 Other Disease Market Share by Region, 2022-2032 (%)
5 Global Dermatology Drugs Market Analysis by Route of Administration
5.1 Key Findings
5.2 Route of Administration Segment Growth Prospects
5.3 Global Dermatology Drugs Market Size Estimation and Forecast by Route of Administration
5.4 Global Dermatology Drugs Market Share by Route of Administration, 2022 & 2032
5.5 Topical
5.5.1 Topical Market Forecast by Region, 2022-2032 (US$ Bn)
5.5.2 Topical Market Share by Region, 2022-2032 (%)
5.6 Oral
5.6.1 Oral Market Forecast by Region, 2022-2032 (US$ Bn)
5.6.2 Oral Market Share by Region, 2022-2032 (%)
5.7 Parenteral
5.7.1 Parenteral Market Forecast by Region, 2022-2032 (US$ Bn)
5.7.2 Parenteral Market Share by Region, 2022-2032 (%)
6 Global Dermatology Drugs Market Analysis by Generics/Biologics
6.1 Key Findings
6.2 Segment Growth Prospects, By Type
6.3 Global Dermatology Drugs Market Share by Generics/Biologics, 2022 & 2032
6.3.1 Dermatology Drugs Market, By Generics
6.3.1.1 Generic Drugs Market Size Estimation and Forecast
6.3.2 Dermatology Drugs Market, By Branded/ Biologics
6.3.2.1 Biologic Drugs Market Size Estimation and Forecast
7 Global Dermatology Drugs Market Analysis by Region
7.1 Key Findings
7.2 Regional Market Size Estimation and Forecast
7.3 COVID-19 Impact Analysis: Recovery Scenarios (V, U, W, L)
8 North America Dermatology Drugs Market Analysis
8.1 Key Findings
8.2 North America Dermatology Drugs Market Attractiveness Index
8.3 North America Dermatology Drugs Market by Country, 2022, 2027 & 2032 (US$ bn)
8.4 North America Dermatology Drugs Market Size Estimation and Forecast by Country
8.5 North America Dermatology Drugs Market Size Estimation and Forecast by Disease
8.6 North America Dermatology Drugs Market Size Estimation and Forecast by Route of Administration
8.7 U.S.
8.7.1 U.S. Dermatology Drugs Market by Disease
8.7.2 U.S. Dermatology Drugs Market by Route of Administration
8.8 Canada
8.8.1 Canada Dermatology Drugs Market by Disease
8.8.2 Canada Dermatology Drugs Market by Route of Administration
9 Europe Dermatology Drugs Market Analysis
9.1 Key Findings
9.2 Europe Dermatology Drugs Market Attractiveness Index
9.3 Europe Dermatology Drugs Market by Country, 2022, 2027 & 2032 (US$ bn)
9.4 Europe Dermatology Drugs Market Size Estimation and Forecast by Country
9.5 Europe Dermatology Drugs Market Size Estimation and Forecast by Disease
9.6 Europe Dermatology Drugs Market Size Estimation and Forecast by Route of Administration
9.7 Germany
9.7.1 Germany Dermatology Drugs Market by Disease
9.7.2 Germany Dermatology Drugs Market by Route of Administration
9.8 U.K.
9.8.1 U.K. Dermatology Drugs Market by Disease
9.8.2 U.K. Dermatology Drugs Market by Route of Administration
9.9 France
9.9.1 France Dermatology Drugs Market by Disease
9.9.2 France Dermatology Drugs Market by Route of Administration
9.10 Italy
9.10.1 Italy Dermatology Drugs Market by Disease
9.10.2 Italy Dermatology Drugs Market by Route of Administration
9.11 Spain
9.11.1 Spain Dermatology Drugs Market by Disease
9.11.2 Spain Dermatology Drugs Market by Route of Administration
9.12 Russia
9.12.1 Russia Dermatology Drugs Market by Disease
9.12.2 Russia Dermatology Drugs Market by Route of Administration
9.13 Rest of Europe
9.13.1 Rest of Europe Dermatology Drugs Market by Disease
9.13.2 Rest of Europe Dermatology Drugs Market by Route of Administration
10 Asia Pacific Dermatology Drugs Market Analysis
10.1 Key Findings
10.2 Asia Pacific Dermatology Drugs Market Attractiveness Index
10.3 Asia Pacific Dermatology Drugs Market by Country, 2022, 2027 & 2032 (US$ bn)
10.4 Asia Pacific Dermatology Drugs Market Size Estimation and Forecast by Country
10.5 Asia Pacific Dermatology Drugs Market Size Estimation and Forecast by Disease
10.6 Asia Pacific Dermatology Drugs Market Size Estimation and Forecast by Route of Administration
10.7 Japan
10.7.1 Japan Dermatology Drugs Market by Disease
10.7.2 Japan Dermatology Drugs Market by Route of Administration
10.8 China
10.8.1 China Dermatology Drugs Market by Disease
10.8.2 China Dermatology Drugs Market by Route of Administration
10.9 India
10.9.1 India Dermatology Drugs Market by Disease
10.9.2 India Dermatology Drugs Market by Route of Administration
10.10 South Korea
10.10.1 South Korea Dermatology Drugs Market by Disease
10.10.2 South Korea Dermatology Drugs Market by Route of Administration
10.11 Australia
10.11.1 Australia Dermatology Drugs Market by Disease
10.11.2 Australia Dermatology Drugs Market by Route of Administration
10.12 Rest of APAC
10.12.1 Rest of APAC Dermatology Drugs Market by Disease
10.12.2 Rest of APAC Dermatology Drugs Market by Route of Administration
11 Latin America Dermatology Drugs Market Analysis
11.1 Key Findings
11.2 Latin America Dermatology Drugs Market Attractiveness Index
11.3 Latin America Dermatology Drugs Market by Country, 2022, 2027 & 2032 (US$ bn)
11.4 Latin America Dermatology Drugs Market Size Estimation and Forecast by Country
11.5 Latin America Dermatology Drugs Market Size Estimation and Forecast by Disease
11.6 Latin America Dermatology Drugs Market Size Estimation and Forecast by Route of Administration
11.7 Brazil
11.7.1 Brazil Dermatology Drugs Market by Disease
11.7.2 Brazil Dermatology Drugs Market by Route of Administration
11.8 Mexico
11.8.1 Mexico Dermatology Drugs Market by Disease
11.8.2 Mexico Dermatology Drugs Market by Route of Administration
11.9 Rest of Latin America
11.9.1 Rest of LATAM Dermatology Drugs Market by Disease
11.9.2 Rest of LATAM Dermatology Drugs Market by Route of Administration
12 MEA Dermatology Drugs Market Analysis
12.1 Key Findings
12.2 MEA Dermatology Drugs Market Attractiveness Index
12.3 MEA Dermatology Drugs Market by Country, 2022, 2027 & 2032 (US$ bn)
12.4 MEA Dermatology Drugs Market Size Estimation and Forecast by Country
12.5 MEA Dermatology Drugs Market Size Estimation and Forecast by Disease
12.6 MEA Dermatology Drugs Market Size Estimation and Forecast by Route of Administration
12.7 South Africa
12.7.1 South Africa Dermatology Drugs Market by Disease
12.7.2 South Africa Dermatology Drugs Market by Route of Administration
12.8 GCC
12.8.1 GCC Dermatology Drugs Market by Disease
12.8.2 GCC Dermatology Drugs Market by Route of Administration
12.9 Rest of MEA
12.9.1 Rest of MEA Dermatology Drugs Market by Disease
12.9.2 Rest of MEA Dermatology Drugs Market by Route of Administration
13 Competitive Landscape
13.1 Company Share Analysis
13.2 Key Business Strategy Analysis
14 Company Profiles
14.1 Pfizer
14.1.1 Company Snapshot
14.1.2 Company Overview
14.1.3 Financial Analysis
14.1.4 Product Benchmarking
14.1.5 Strategic Outlook
14.2 Merck
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Financial Analysis
14.2.4 Product Benchmarking
14.2.5 Strategic Outlook
14.3 GSK
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 AbbVie
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.4 Product Benchmarking
14.4.5 Strategic Outlook
14.5 Janssen Pharma
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.4 Product Benchmarking
14.5.5 Strategic Outlook
14.6 BMS
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.4 Product Benchmarking
14.6.5 Strategic Outlook
14.7 Roche
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.4 Product Benchmarking
14.7.5 Strategic Outlook
14.8 Abbott Laboratories
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Financial Analysis
14.8.4 Product Benchmarking
14.8.5 Strategic Outlook
14.9 Bayer Pharmaceuticals
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.4 Product Benchmarking
14.9.5 Strategic Outlook
14.10 Zydus Cadila Healthcare Pharmaceutical
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.4 Product Benchmarking
14.10.5 Strategic Outlook
14.11 Cipla Pharmaceutical
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.4 Product Benchmarking
14.11.5 Strategic Outlook
14.12 Dr. Reddy’s Laboratories
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.4 Product Benchmarking
14.12.5 Strategic Outlook
14.13 Eli Lilly and Company
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Financial Analysis
14.13.4 Product Benchmarking
14.13.5 Strategic Outlook
14.14 Glenmark Pharmaceuticals Limited
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Financial Analysis
14.14.4 Product Benchmarking
14.14.5 Strategic Outlook
14.15 Lupin Limited
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Financial Analysis
14.15.4 Product Benchmarking
14.15.5 Strategic Outlook
14.16 Sanofi Pasteur Pharmaceutical
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Financial Analysis
14.16.4 Product Benchmarking
14.16.5 Strategic Outlook
14.17 Sun Pharmaceutical Industries Limited
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Financial Analysis
14.17.4 Product Benchmarking
14.17.5 Strategic Outlook
14.18 Taro Pharmaceutical Industries Ltd.
14.18.1 Company Snapshot
14.18.2 Company Overview
14.18.3 Financial Analysis
14.18.4 Product Benchmarking
14.18.5 Strategic Outlook
15 Conclusion and Recommendations
15.1 Concluding Remarks from Visiongain
15.2 Recommendations for Market Players
List of Tables
Table 1 Global Dermatology Drugs Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 Dermatology Drugs Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (V-shaped Recovery)
Table 3 Dermatology Drugs Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (U-shaped Recovery)
Table 4 Dermatology Drugs Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (W-shaped Recovery)
Table 5 Dermatology Drugs Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (L-shaped Recovery)
Table 6 Dermatological Drugs Diseases Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 7 Cost of Psoriasis Therapies in A Typical Western European Country ($)
Table 8 Psoriasis Drug Pipeline
Table 9 Psoriasis Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 10 Global Products Undergoing Research as Potential Treatments for Dermatitis
Table 11 Dermatitis Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 12 Global Potential Products for Acne Treatment
Table 13 Acne Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 14 Global Antifungals for Superficial Fungal Infections
Table 15 Global Antiviral Drugs Available
Table 16 Global Potential Drug Candidates for Skin Infection Treatments
Table 17 Skin Infection Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 18 Antiaging Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 19 Antifungal Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 20 Skin cancer Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 21 Hair Loss Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 22 Hyperpigmentation Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 23 Other Diseases Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 24 Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 25 Topical Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 26 Oral Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 27 Parenteral Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 28 Dermatological Drugs Generics Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 29 Dermatological Drugs Biologics Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 30 Dermatological Drugs Market, By Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 31 Dermatology Drugs Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (V-shaped Recovery)
Table 32 Dermatology Drugs Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (U-shaped Recovery)
Table 33 Dermatology Drugs Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (W-shaped Recovery)
Table 34 Dermatology Drugs Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (L-shaped Recovery)
Table 35 North America Dermatological Drugs Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 36 North America Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 37 North America Dermatological Drugs Market by Psoriasis Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 38 North America Dermatological Drugs Market by Dermatitis Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 39 North America Dermatological Drugs Market by Acne Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 40 North America Dermatological Drugs Market by Skin Infections Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 41 North America Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 42 US Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 43 US Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 44 US Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 45 Canada Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 46 Canada Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 47 Canada Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 48 Europe Dermatological Drugs Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 49 Europe Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 50 Europe Dermatological Drugs Market by Psoriasis Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 51 Europe Dermatological Drugs Market by Dermatitis Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 52 Europe Dermatological Drugs Market by Acne Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 53 Europe Dermatological Drugs Market by Skin Infections Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 54 Europe Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 55 Germany Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 56 Germany Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 57 Germany Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 58 UK Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 59 UK Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 60 UK Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 61 France Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 62 France Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 63 France Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 64 Italy Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 65 Italy Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 66 Italy Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 67 Spain Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 68 Spain Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 69 Spain Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 70 Russia Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 71 Russia Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 72 Russia Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 73 Rest of Europe Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 74 Rest of Europe Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 75 Rest of Europe Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 76 Asia Pacific Dermatological Drugs Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 77 Asia Pacific Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 78 Asia-Pacific Dermatological Drugs Market by Psoriasis Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 79 Asia-Pacific Dermatological Drugs Market by Dermatitis Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 80 Asia-Pacific Dermatological Drugs Market by Acne Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 81 Asia-Pacific Dermatological Drugs Market by Skin Infections Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 82 Asia Pacific Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 83 Japan Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 84 Japan Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 85 Japan Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 86 China Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 87 China Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 88 China Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 89 India Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 90 India Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 91 India Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 92 South Korea Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 93 South Korea Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 94 South Korea Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 95 Australia Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 96 Australia Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 97 Australia Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 98 Rest of Asia Pacific Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 99 Rest of Asia Pacific Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 100 Rest of Asia Pacific Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 101 Latin America Dermatological Drugs Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 102 Latin America Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 103 LATAM Dermatological Drugs Market by Psoriasis Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 104 LATAM Dermatological Drugs Market by Dermatitis Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 105 LATAM Dermatological Drugs Market by Acne Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 106 LATAM Dermatological Drugs Market by Skin Infections Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 107 Latin America Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 108 Brazil Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 109 Brazil Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 110 Brazil Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 111 Mexico Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 112 Mexico Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 113 Mexico Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 114 Rest of Latin America Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 115 Rest of LATAM Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 116 Rest of LATAM Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 117 MEA Dermatological Drugs Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 118 MEA Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 119 MEA Dermatological Drugs Market by Psoriasis Drugs, 2022-2032 (USD Bn, AGR (%), CAGR(%))
Table 120 MEA Dermatological Drugs Market by Dermatitis Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 121 MEA Dermatological Drugs Market by Acne Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 122 MEA Dermatological Drugs Market by Skin Infections Drugs, 2022-2032 (US$ Bn, AGR (%), CAGR(%))
Table 123 MEA Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 124 South Africa Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 125 South Africa Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 126 South Africa Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 127 GCC Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 128 GCC Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 129 GCC Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 130 Rest of MEA Dermatological Drugs Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 131 Rest of MEA Dermatological Drugs Disease Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 132 Rest of MEA Dermatological Drugs Route of Administration Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 133 Key Business Strategies Adopted by Key Players in Global Dermatology Drugs Market
Table 134 Pfizer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 135 Pfizer: Product Benchmarking
Table 136 Pfizer Inc: Company Product Pipeline
Table 137 Pfizer Inc: Company Recent Developments
Table 138 Merck: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 139 Merck: Product Benchmarking
Table 140 Merck: Company Recent Developments
Table 141 GSK: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 142 GSK: Product Benchmarking
Table 143 GlaxoSmithKline: Company Product Pipeline
Table 144 GlaxoSmithKline: Company Recent Developments
Table 145 AbbVie: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
Table 146 AbbVie: Product Benchmarking
Table 147 AbbVie Inc: Company Product Pipeline
Table 148 AbbVie Inc: Company Recent Developments
Table 149 Janssen Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 150 Janssen Pharma: Product Benchmarking
Table 151 Janssen Pharma: Company Product Pipeline
Table 152 Janssen Pharma: Company Recent Developments
Table 153 BMS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
Table 154 BMS: Product Benchmarking
Table 155 Bristol-Myers Squibb: Company Product Pipeline
Table 156 Bristol-Myers Squibb: Company Recent Developments
Table 157 Roche: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 158 Roche: Product Benchmarking
Table 159 F. Hoffmann-La Roche Ltd: Company Recent Developments
Table 160 Abbott Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 161 Bayer Pharmaceuticals: Product Benchmarking
Table 162 Bayer Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 163 Bayer Pharmaceuticals: Product Benchmarking
Table 164 Bayer Pharmaceuticals: Company Recent Developments
Table 165 Zydus Cadila Healthcare Pharmaceutical: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 166 Zydus Cadila Healthcare Pharmaceutical: Product Benchmarking
Table 167 Zydus Cadila Healthcare Pharmaceuticals: Company Recent Developments
Table 168 Cipla Pharmaceutical: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 169 Cipla Pharmaceutical: Product Benchmarking
Table 170 Cipla Pharmaceutical: Company Recent Developments
Table 171 Dr. Reddy’s Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 172 Dr. Reddy’s Laboratories: Product Benchmarking
Table 173 Dr. Reddy’s Laboratories: Company Recent Developments
Table 174 Eli Lilly and Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 175 Eli Lilly and Company: Product Benchmarking
Table 176 Eli Lilly and Company: Company Product Pipeline
Table 177 Eli Lilly and Company: Company Recent Developments
Table 178 Glenmark Pharmaceuticals Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 179 Glenmark Pharmaceuticals Limited: Product Benchmarking
Table 180 Glenmark Pharmaceuticals Limited: Company Product Pipeline
Table 181 Glenmark Pharmaceuticals Limited: Company Recent Developments
Table 182 Lupin Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 183 Lupin Limited: Product Benchmarking
Table 184 Lupin Limited: Company Recent Developments
Table 185 Sanofi Pasteur Pharmaceutical: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 186 Sanofi Pasteur Pharmaceutical: Product Benchmarking
Table 187 Sanofi Pasteur Pharmaceutical: Company Product Pipeline
Table 188 Sanofi Pasteur Pharmaceutical: Company Recent Developments
Table 189 Sun Pharmaceutical Industries Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 190 Sun Pharmaceutical Industries Limited: Product Benchmarking
Table 191 Sun Pharmaceutical Industries Limited: Company Product Pipeline
Table 192 Sun Pharmaceutical Industries Limited: Company Recent Developments
Table 193 Taro Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 194 Taro Pharmaceutical Industries Ltd.: Product Benchmarking
Table 195 Taro Pharmaceutical Industries Ltd: Company Recent Developments
List of Figures
Figure 1 Global Dermatology Drugs Market Segmentation
Figure 2 Global Dermatology Drugs Market Forecast by Region: Market Attractiveness Index
Figure 3 Global Dermatology Drugs Market by Disease: Market Attractiveness Index
Figure 4 Global Dermatology Drugs Market by Route of Administration: Market Attractiveness Index
Figure 5 Global Dermatology Drugs Market: Market Dynamics
Figure 6 Global COVID Impact Analysis: Dermatology Drugs Market Recovery Scenarios
Figure 7 Global Dermatology Drugs Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 8 Global Dermatology Drugs Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 9 Global Dermatology Drugs Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 10 Global Dermatology Drugs Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 11 Global Dermatology Drugs Market: Porter’s Five Forces Analysis
Figure 12 Global Dermatology Drugs Market Forecast by Disease 2022, 2027, 2032 (Revenue, CAGR %)
Figure 13 Global Dermatology Drugs Market Share Forecast by Disease, 2022, 2027, 2032 (%)
Figure 14 Global Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 15 Psoriasis Market Forecast by Region, 2022-2032 (US$ billion)
Figure 16 Psoriasis Market Share Forecast by Region, 2022-2032 (%)
Figure 17 Dermatitis Market Forecast by Region, 2022-2032 (US$ billion)
Figure 18 Dermatitis Market Share Forecast by Region, 2022-2032 (%)
Figure 19 Acne Market Forecast by Region, 2022-2032 (US$ billion)
Figure 20 Acne Market Share Forecast by Region, 2022-2032 (%)
Figure 21 Skin Infections Market Forecast by Region, 2022-2032 (US$ billion)
Figure 22 Skin Infections Market Share Forecast by Region, 2022-2032 (%)
Figure 23 Antiaging Market Forecast by Region, 2022-2032 (US$ billion)
Figure 24 Antiaging Market Share Forecast by Region, 2022-2032 (%)
Figure 25 Antifungal Market Forecast by Region, 2022-2032 (US$ billion)
Figure 26 Antifungal Market Share Forecast by Region, 2022-2032 (%)
Figure 27 Skin Cancer Market Forecast by Region, 2022-2032 (US$ billion)
Figure 28 Skin Cancer Market Share Forecast by Region, 2022-2032 (%)
Figure 29 Hair Loss Market Forecast by Region, 2022-2032 (US$ billion)
Figure 30 Hair Loss Market Share Forecast by Region, 2022-2032 (%)
Figure 31 Hyperpigmentation Market Forecast by Region, 2022-2032 (US$ billion)
Figure 32 Hyperpigmentation Market Share Forecast by Region, 2022-2032 (%)
Figure 33 Other Disease Market Forecast by Region, 2022-2032 (US$ billion)
Figure 34 Other Disease Market Share Forecast by Region, 2022-2032 (%)
Figure 35 Global Dermatology Drugs Market Forecast by Route of Administration 2022, 2027, 2032 (Revenue, CAGR%)
Figure 36 Global Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 37 Global Dermatology Drugs Market Share Forecast by Route of Administration, 2022, 2032 (%)
Figure 38 Topical Market Forecast by Region, 2022-2032 (US$ billion)
Figure 39 Topical Market Share Forecast by Region, 2022-2032 (%)
Figure 40 Oral Market Forecast by Region, 2022-2032 (US$ billion)
Figure 41 Oral Market Share Forecast by Region, 2022-2032 (%)
Figure 42 Parenteral Market Forecast by Region, 2022-2032 (US$ billion)
Figure 43 Parenteral Market Share Forecast by Region, 2022-2032 (%)
Figure 44 Global Dermatology Drugs Market Forecast by Generics/Biologics 2022, 2027, 2032 (Revenue, CAGR %)
Figure 45 Global Dermatology Drugs Market Share Forecast by Generics/Biologics, 2022, 2032 (%)
Figure 46 Global Dermatology Drugs Market Forecast by Generics, 2022-2032 (US$ billion, AGR %)
Figure 47 Global Dermatology Drugs Market Forecast by Biologics, 2022-2032 (US$ billion, AGR %)
Figure 48 Global Dermatology Drugs Market Forecast by Region 2022, 2027, 2032 (Revenue), C
Figure 49 Global Dermatology Drugs Market Share Forecast by Region 2022, 2027, 2032(%)
Figure 50 Global Dermatology Drugs Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Figure 51 Global Dermatology Drugs Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 52 Global Dermatology Drugs Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 53 Global Dermatology Drugs Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 54 Global Dermatology Drugs Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 55 North America Dermatology Drugs Market Attractiveness Index, 2022
Figure 56 North America Dermatology Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 57 North America Dermatology Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 58 North America Dermatology Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 59 North America Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 60 North America Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 61 North America Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 62 North America Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 63 U.S. Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 64 U.S. Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 65 U.S. Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 66 U.S. Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 67 U.S. Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 68 Canada Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 69 Canada Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 70 Canada Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 71 Canada Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 72 Canada Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 73 Europe Dermatology Drugs Market Attractiveness Index
Figure 74 Europe Dermatology Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 75 Europe Dermatology Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 76 Europe Dermatology Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 77 Europe Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 78 Europe Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 79 Europe Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 80 Europe Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 81 Germany Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 82 Germany Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 83 Germany Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 84 Germany Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 85 Germany Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 86 UK Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 87 U.K. Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 88 U.K. Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 89 U.K. Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 90 U.K. Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 91 France Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 92 France Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 93 France Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 94 France Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 95 France Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 96 Italy Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 97 Italy Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 98 Italy Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 99 Italy Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 100 Italy Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 101 Spain Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 102 Spain Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 103 Spain Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 104 Spain Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 105 Spain Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 106 Russia Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 107 Russia Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 108 Russia Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 109 Russia Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 110 Russia Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 111 Rest of Europe Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 112 Rest of Europe Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 113 Rest of Europe Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 114 Rest of Europe Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 115 Rest of Europe Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 116 Asia Pacific Dermatology Drugs Market Attractiveness Index
Figure 117 Asia Pacific Dermatology Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 118 Asia Pacific Dermatology Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 119 Asia Pacific Dermatology Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 120 Asia Pacific Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 121 Asia Pacific Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 122 Asia Pacific Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 123 Asia Pacific Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 124 Japan Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 125 Japan Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 126 Japan Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 127 Japan Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 128 Japan Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 129 China Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 130 China Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 131 China Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 132 China Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 133 China Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 134 India Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 135 India Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 136 India Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 137 India Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 138 India Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 139 South Korea Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 140 South Korea Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 141 South Korea Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 142 South Korea Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 143 South Korea Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 144 Australia Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 145 Australia Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 146 Australia Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 147 Australia Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 148 Australia Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 149 Rest of Asia Pacific Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 150 Rest of APAC Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 151 Rest of APAC Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 152 Rest of APAC Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 153 Rest of APAC Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 154 Latin America Dermatology Drugs Market Attractiveness Index
Figure 155 Latin America Dermatology Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 156 Latin America Dermatology Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 157 Latin America Dermatology Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 158 Latin America Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 159 Latin America Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 160 Latin America Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 161 Latin America Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 162 Brazil Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 163 Brazil Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 164 Brazil Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 165 Brazil Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 166 Brazil Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 167 Mexico Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 168 Mexico Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 169 Mexico Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 170 Mexico Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 171 Mexico Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 172 Rest of LATAM Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 173 Rest of LATAM Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 174 Rest of LATAM Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 175 Rest of LATAM Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 176 Rest of LATAM Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 177 MEA Dermatology Drugs Market Attractiveness Index
Figure 178 MEA Dermatology Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 179 MEA Dermatology Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 180 MEA Dermatology Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 181 MEA Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 182 MEA Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 183 MEA Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 184 MEA Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 185 South Africa Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 186 South Africa Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 187 South Africa Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 188 South Africa Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 189 South Africa Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 190 GCC Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 191 GCC Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 192 GCC Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 193 GCC Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 194 GCC Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 195 Rest of MEA Dermatology Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 196 Rest of MEA Dermatology Drugs Market Forecast by Disease, 2022-2032 (US$ billion, AGR %)
Figure 197 Rest of MEA Dermatology Drugs Market Share Forecast by Disease, 2022 & 2032 (%)
Figure 198 Rest of MEA Dermatology Drugs Market Forecast by Route of Administration, 2022-2032 (US$ billion, AGR %)
Figure 199 Rest of MEA Dermatology Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 200 Global Dermatology Drugs Market: Company Ranking Analysis, 2021
Figure 201 Pfizer: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 202 Pfizer: Regional Market Shares, 2021
Figure 203 Pfizer: Gross Profit, 2019-2021 (US$ million, AGR%)
Figure 204 Pfizer: R&D, 2019-2021 (US$ million, AGR%)
Figure 205 Merck: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 206 Merck: Regional Market Shares, 2021
Figure 207 Merck: Income from Continuing Operations before Taxes, 2019-2021 (US$ million, AGR %)
Figure 208 Merck: R&D, 2019-2021 (US$ million, AGR %)
Figure 209 GSK: Net Revenue, 2019-2021 (US$ million, AGR %)
Figure 210 GSK: Regional Market Shares, 2021
Figure 211 GSK: Gross Profit, 2019-2021 (US$ million, AGR %)
Figure 212 GSK: R&D, 2019-2021 (US$ million, AGR %)
Figure 213 AbbVie: Net Revenue, 2019-2021 (US$ million, AGR %)
Figure 214 AbbVie: Regional Market Shares, 2021
Figure 215 AbbVie: Operating Earnings, 2019-2021 (US$ million, AGR %)
Figure 216 AbbVie: R&D, 2019-2021 (US$ million, AGR %)
Figure 217 Janssen Pharma: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 218 Janssen Pharma: Regional Market Shares, 2021
Figure 219 Janssen Pharma: Gross Profit, 2019-2021 (US$ million, AGR%)
Figure 220 Janssen Pharma: R&D, 2019-2021 (US$ million, AGR%)
Figure 221 BMS: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 222 BMS: Regional Market Shares, 2021
Figure 223 BMS: Net Earnings, 2019-2021 (US$ million, AGR%)
Figure 224 BMS: R&D, 2019-2021 (US$ million, AGR %)
Figure 225 Roche: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 226 Roche: Regional Market Shares, 2021
Figure 227 Roche: Operating Profit, 2019-2021 (US$ million, AGR%)
Figure 228 Roche: R&D, 2019-2021 (US$ million, AGR%)
Figure 229 Abbott Laboratories: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 230 Abbott Laboratories: Regional Market Shares, 2021
Figure 231 Abbott Laboratories: Net Earnings, 2019-2021 (US$ million, AGR%)
Figure 232 Abbott Laboratories: R&D, 2019-2021 (US$ million, AGR%)
Figure 233 Bayer Pharmaceuticals: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 234 Bayer Pharmaceuticals: Regional Market Shares, 2021
Figure 235 Bayer Pharmaceuticals: EBITDA, 2019-2021 (US$ million, AGR%)
Figure 236 Bayer Pharmaceuticals: R&D, 2019-2021 (US$ million, AGR%)
Figure 237 Zydus Cadila Healthcare Pharmaceutical: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 238 Zydus Cadila Healthcare Pharmaceutical: Regional Market Shares, 2021
Figure 239 Zydus Cadila Healthcare Pharmaceutical: Net Profit, 2019-2021 (US$ million, AGR%)
Figure 240 Zydus Cadila Healthcare Pharmaceutical: R&D, 2019-2021 (US$ million, AGR%)
Figure 241 Cipla Pharmaceutical: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 242 Cipla Pharmaceutical: Regional Market Shares, 2021
Figure 243 Cipla Pharmaceutical: EBITDA, 2019-2021 (US$ million, AGR%)
Figure 244 Cipla Pharmaceutical: R&D, 2019-2021 (US$ million, AGR%)
Figure 245 Dr. Reddy’s Laboratories: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 246 Dr. Reddy’s Laboratories: Regional Market Shares, 2021
Figure 247 Dr. Reddy’s Laboratories: EBITDA, 2019-2021 (US$ million, AGR%)
Figure 248 Dr. Reddy’s Laboratories: R&D, 2019-2021 (US$ million, AGR%)
Figure 249 Eli Lilly and Company: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 250 Eli Lilly and Company: Regional Market Shares, 2021
Figure 251 Eli Lilly and Company: Net Income, 2019-2021 (US$ million, AGR%)
Figure 252 Eli Lilly and Company: R&D, 2019-2021 (US$ million, AGR%)
Figure 253 Glenmark Pharmaceuticals Limited: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 254 Glenmark Pharmaceuticals Limited: Regional Market Shares, 2021
Figure 255 Lupin Limited: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 256 Lupin Limited: Regional Market Shares, 2021
Figure 257 Lupin Limited: Net Profit/Loss, 2019-2021 (US$ million, AGR%)
Figure 258 Lupin Limited: R&D, 2019-2021 (US$ million, AGR%)
Figure 259 Sanofi Pasteur Pharmaceutical: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 260 Sanofi Pasteur Pharmaceutical: Regional Market Shares, 2021
Figure 261 Sanofi Pasteur Pharmaceutical: Net Income, 2019-2021 (US$ million, AGR%)
Figure 262 Sanofi Pasteur Pharmaceutical: R&D, 2019-2021 (US$ million, AGR%)
Figure 263 Sun Pharmaceutical Industries Limited: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 264 Sun Pharmaceutical Industries Limited: Regional Market Shares, 2021
Figure 265 Sun Pharmaceutical Industries Limited: Net Profit/Loss, 2019-2021 (US$ million, AGR%)
Figure 266 Sun Pharmaceutical Industries Limited: R&D, 2019-2021 (US$ million, AGR%)
Figure 267 Taro Pharmaceutical Industries Ltd.: Net Revenue, 2020-2022 (US$ million, AGR%)
Figure 268 Taro Pharmaceutical Industries Ltd.: Regional Market Shares, 2022
Figure 269 Taro Pharmaceutical Industries Ltd.: Net Income, 2020-2022 (US$ million, AGR%)
Figure 270 Taro Pharmaceutical Industries Ltd.: R&D, 2020-2022 (US$ million, AGR%)
ページTOPに戻る
Visiongain社の医薬・化学品分野での最新刊レポート
本レポートと同じKEY WORD（）の最新刊レポート
- 本レポートと同じKEY WORDの最新刊レポートはありません。
よくあるご質問
Visiongain社はどのような調査会社ですか?
英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る
調査レポートの納品までの日数はどの程度ですか?
在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。
注文の手続きはどのようになっていますか?
1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。
お支払方法の方法はどのようになっていますか?
納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。
データリソース社はどのような会社ですか?
当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。
|
|
